KCL Capital’s ProKidney PROK Stock Holding History

KCL Capital’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50,000	Closed	-$507K	–	56
2021 Q2	$507K	Buy	+50,000	New	+$506K	0.07%	42

Other funds holding PROK

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

KCL Capital's PROK Position: Q3 2021 in Review

KCL Capital sold out of ProKidney (PROK) in Q3 2021, closing a stake of 50,000 shares — an estimated $507K sold.

KCL Capital first reported a position in PROK in Q2 2021 and held it in 1 quarter. The position peaked at $507K in Q2 2021. 84 funds tracked by Wall St. Rank hold PROK as of Q3 2021.

KCL Capital reported no remaining ProKidney position as of Q3 2021 after selling out during the quarter.
KCL Capital sold 50,000 ProKidney shares in Q3 2021, an estimated $507K.
KCL Capital first reported a position in ProKidney in Q2 2021 and held it in 1 quarter.
KCL Capital's ProKidney position peaked at $507K in Q2 2021.
84 funds tracked by Wall St. Rank held ProKidney as of Q3 2021.

Based on KCL Capital's 13F filing for Q3 2021, filed 15 Nov 2021.